EG 427
Mikael Contrastin currently serves as the VP Strategy & Business Development at EG427 since March 2021. Prior to this, Mikael held roles as an Investment Director and Head of projects and technology transfer at SATT PARIS SACLAY from December 2014 to February 2021. Mikael also worked as a Technology Transfer Project Manager at Renault from October 2008 to November 2014. With a background in engineering and design, Mikael has a Master's degree in IT, Economics, and Design, Project & Innovation management from École Polytechnique.
This person is not in any teams
EG 427
EG 427 is a French biotechnology company that pioneers a new approach in gene therapy called pinpoint gene therapy.